Hepion Pharmaceuticals Announces Passing Of Key Safety Milestone In Phase 2b 'ASCEND-NASH' Trial Of Rencofilstat
Portfolio Pulse from Benzinga Newsdesk
Hepion Pharmaceuticals (NASDAQ:HEPA) has received clearance from the Data and Safety Monitoring Board (DSMB) to proceed without modification in its Phase 2b ASCEND-NASH trial of Rencofilstat. The trial is on track to complete enrollment in Q1 2024, and initial subjects are approaching the later stages of the 12-month trial.
June 15, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hepion Pharmaceuticals' Phase 2b ASCEND-NASH trial of Rencofilstat has received clearance from the DSMB to proceed without modification, with enrollment on track for Q1 2024.
The clearance from the DSMB to proceed without modification in the Phase 2b ASCEND-NASH trial is a positive development for Hepion Pharmaceuticals. This indicates that the trial is progressing as planned and that the safety profile of Rencofilstat is satisfactory. As a result, this news is likely to have a positive short-term impact on Hepion's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100